Mechanism of inhibition of tumour growth by aspirin and indomethacin
- PMID: 365211
- PMCID: PMC2009769
- DOI: 10.1038/bjc.1978.237
Mechanism of inhibition of tumour growth by aspirin and indomethacin
Abstract
The growth of a 3-methylcholanthrene-induced fibrosarcoma of C3H mice was inhibited by aspirin and indomethacin. While the tumour contained relatively high concentrations of PGE2-like material, that were markedly diminished by indomethacin treatment, our results did not confirm the recently proposed hypothesis that the anti-tumour effect arises from a restoration of depressed immune function. For example, mice that had completely eliminated their tumours under indomethacin administration were not immune to rechallenge. The tumour-bearing animals were not non-specifically immunodepressed, as their splenic PFC responses against SRBC were enhanced. However, while indomethacin augmented the PFC response in normal mice, this adjuvant effect was depressed in tumour-bearing animals. The spleen-cell PHA responses of tumour bearers were severely depressed, and such cells suppressed the PHA response of normal cells. Only after prolonged indomethacin treatment did animals (with comparable tumour burdens) show weak PHA responses and somewhat diminished suppressive activity. Possible alternative mechanisms, such as direct cytotoxicity, or inhibition of inflammation, phosphodiesterase activity, blood coagulation or calcium availability were not implicated (nor definitively excluded) in the anti-tumour effect.
Similar articles
-
Piroxicam, indomethacin and aspirin action on a murine fibrosarcoma. Effects on tumour-associated and peritoneal macrophages.Clin Exp Immunol. 1991 Nov;86(2):315-21. doi: 10.1111/j.1365-2249.1991.tb05816.x. Clin Exp Immunol. 1991. PMID: 1834380 Free PMC article.
-
Antibody production by spleen cells of mice bearing MCA-induced tumours: search for suppressor cells.Int J Cancer. 1978 Aug 15;22(2):136-41. doi: 10.1002/ijc.2910220206. Int J Cancer. 1978. PMID: 359487
-
Dependence of indomethacin-induced potentiation of murine tumor radioresponse on tumor host immunocompetence.Cancer Res. 1990 Aug 1;50(15):4473-7. Cancer Res. 1990. PMID: 2369725
-
Growth of transplanted tumours in mice treated with macrophages and their products.In Vivo. 1995 Sep-Oct;9(5):479-88. In Vivo. 1995. PMID: 8900927
-
Cell-mediated immune responses to syngeneic ultraviolet-induced tumours. V. Assessment of accessory and antigen-presenting cell capabilities of normal and ultraviolet-irradiated mice in the generation of anti-tumour cytotoxic effector cells in vitro.Immunology. 1982 Sep;47(1):49-59. Immunology. 1982. PMID: 6981587 Free PMC article.
Cited by
-
Anti-inflammation induced by counter-irritation or by treatment with non-steroidal agents inhibits the growth of a tumour of non-detected immunogenicity.Br J Cancer. 1989 Nov;60(5):734-8. doi: 10.1038/bjc.1989.349. Br J Cancer. 1989. PMID: 2803950 Free PMC article.
-
Prognostic significance of plasma prostaglandin E concentration in patients with head and neck cancer.J Cancer Res Clin Oncol. 1992;118(4):308-13. doi: 10.1007/BF01208621. J Cancer Res Clin Oncol. 1992. PMID: 1577849 Free PMC article.
-
Treatment of mouse carcinoma in vivo with a prostaglandin E2 analogue and indomethacin.Br J Cancer. 1985 Aug;52(2):245-9. doi: 10.1038/bjc.1985.184. Br J Cancer. 1985. PMID: 4027166 Free PMC article.
-
Role of Acetylsalicylic Acid in Cytokine Stimulation of Macrophages in Antibody-Dependent Cellular Cytotoxicity (ADCC).Mediators Inflamm. 1994;3(6):419-24. doi: 10.1155/S0962935194000591. Mediators Inflamm. 1994. PMID: 18475590 Free PMC article.
-
A role for prostaglandins in the suppression of cutaneous cellular immunity and tumour development in benzo(a)pyrene- but not dimethylbenz(a)anthracene-treated mice.Clin Exp Immunol. 1991 Jul;85(1):9-13. doi: 10.1111/j.1365-2249.1991.tb05674.x. Clin Exp Immunol. 1991. PMID: 1906386 Free PMC article.
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous